Biotech firm's deal in US boosts cardiac safety
Date added:
10/02/2016
MACCLESFIELD biotech company Cyprotex has announced a strategic partnership deal with ion channel specialists Cytocentrics in the US. As part of the agreement, Cytocentrics will provide equipment, cell lines, expertise and training to allow Cyprotex to provide a panel of different ion channel assays from its Watertown site, near Boston. A consortium in the USA known as CiPA (Comprehensive in Vitro Proarrythmia Assay) is currently evaluating an idea for anew regulatory cardiac safety testing using in silico and in vitro methods. CiPA ....
Back to all news